| 卢 婧,王晓静,谭海龙,蒋 浩,孙梦迪.参芍片联合酒石酸美托洛尔片对冠心病心绞痛患者氧化应激、血管内皮功能和心肌损伤标志物的影响[J].,2022,(20):3882-3886 |
| 参芍片联合酒石酸美托洛尔片对冠心病心绞痛患者氧化应激、血管内皮功能和心肌损伤标志物的影响 |
| Effects of Shenshao Tablet Combined with Metoprolol Tartrate Tablet on Oxidative Stress, Vascular Endothelial Function and Myocardial Injury Markers in Patients with Coronary Heart Disease and Angina Pectoris |
| 投稿时间：2022-03-08 修订日期：2022-03-31 |
| DOI：10.13241/j.cnki.pmb.2022.20.016 |
| 中文关键词: 参芍片 酒石酸美托洛尔片 冠心病心绞痛 氧化应激 血管内皮功能 心肌损伤标志物 |
| 英文关键词: Shenshao tablets Metoprolol tartrate tablets Coronary heart disease and angina pectoris Oxidative stress Vascular endothelial function Myocardial injury markers |
| 基金项目:北京市科技计划科研项目（Z161100000516186） |
|
| 摘要点击次数: 885 |
| 全文下载次数: 468 |
| 中文摘要: |
| 摘要 目的：探讨参芍片联合酒石酸美托洛尔片对冠心病心绞痛患者氧化应激、血管内皮功能和心肌损伤标志物的影响。方法：病例选取自我院2018年9月~2021年7月期间收治的110例冠心病心绞痛患者，按照入院的奇偶顺序将患者分为对照组（55例）和观察组（55例），对照组患者接受酒石酸美托洛尔片治疗，观察组患者接受参芍片联合酒石酸美托洛尔片治疗，观察两组临床总有效率、心电图总有效率，对比两组临床症状、氧化应激[超氧化物歧化酶（SOD）、丙二醛（MDA）、谷胱甘肽过氧化物酶（GSH-PX）]、血管内皮功能[内皮素（ET）、血管内皮生长因子（VEGF）、一氧化氮（NO）]和心肌损伤标志物[心肌肌钙蛋白（cTn）、肌酸激酶同工酶（CK-MB）、脑钠肽（BNP）]水平变化，记录两组用药的不良反应发生率。结果：与对照组相比，观察组的临床总有效率、心电图总有效率进一步升高（P<0.05）。观察组治疗12周后心绞痛发作次数较对照组少，心绞痛持续时间较对照组短，6 min步行试验距离长于对照组（P<0.05）。治疗12周后，观察组VEGF、ET水平低于对照组，NO水平高于对照组（P<0.05）。治疗12周后，观察组CK-MB、cTn、BNP水平低于对照组（P<0.05）。治疗12周后，观察组MDA水平低于对照组，SOD、GSH-PX水平高于对照组（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。结论：参芍片联合酒石酸美托洛尔片治疗冠心病心绞痛患者，可促进症状改善，减轻机体氧化应激和血管内皮损伤，发挥较好的心肌保护作用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Shenshao tablets combined with metoprolol tartrate tablets on oxidative stress, vascular endothelial function and myocardial injury markers in patients with coronary heart disease and angina pectoris. Methods: Cases were selected from 110 patients with coronary heart disease and angina pectoris who were treated in our hospital from September 2018 to July 2021, According to the parity order of admission, the patients were divided into control group (55 cases) and observation group (55 cases). The patients in the control group were treated with metoprolol tartrate tablets, and the patients in the observation group were treated with Shenshao tablets combined with metoprolol tartrate tablets. The total clinical effective rate and ECG effective rate of the two groups were observed. The clinical symptoms and oxidative stress [superoxide dismutase (SOD), malondialdehyde (MDA), glutathione peroxidase (GSH-PX)], vascular endothelial function [endothelin (ET), vascular endothelial growth factor (VEGF), nitric oxide (NO)] and myocardial injury markers [cardiac troponin (cTn), creatine kinase isoenzyme (CK-MB), brain natriuretic peptide (BNP)] changes were compared between the two groups, the incidence of adverse reactions in the two groups was recorded. Results: Compared with the control group, the total clinical effective rate and ECG effective rate in the observation group were further increased (P<0.05). 12 weeks after treatment, the number of angina pectoris attacks in the observation group was less than that in the control group, the duration of angina pectoris was shorter than that in the control group, and the 6 min walking test distance was longer than that in the control group (P<0.05). 12 weeks after treatment, the levels of VEGF and ET in the observation group were lower than those in the control group, and the level of NO was higher than that in the control group (P<0.05). 12 weeks after treatment, the levels of CK-MB, cTn and BNP in the observation group were lower than those in the control group (P<0.05). 12 weeks after treatment, the level of MDA in the observation group was lower than that in the control group, and the levels of SOD and GSH-PX were higher than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Shenshao tablet combined with metoprolol tartrate tablet in the treatment of patients with coronary heart disease and angina pectoris can promote the improvement of symptoms, reduce oxidative stress and vascular endothelial injury, and play a good myocardial protective effect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
